Close this search box.

With Proteologix takeout, J&J adds bispecifics for atopic dermatitis, asthma


Lead compound targeting IL-13 and TSLP trails bispecific competitors; second program set to advance behind it

By Paul Bonanos, Director of Biopharma Intelligence

May 16, 2024 5:43 PM UTC

Updated on May 17, 2024 at 9:01 PM UTC

The $850 million takeout of Proteologix will give J&J a bispecific antibody for immunologic diseases that’s ready for the clinic and could compete with programs against the same targets from three other pharmas.

Johnson & Johnson (NYSE:JNJ) said PX128, an antibody targeting IL-13 and TSLP, is ready for Phase I testing to treat atopic dermatitis and asthma. The pharma will gain PX128 in its all-cash deal for Proteologix Inc., a privately held company based in Redwood City, Calif., that has disclosed very little in its history…